Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Telo Genomics Corp ( (TSE:TELO) ) is now available.
Telo Genomics Corp. has closed the second and final tranche of its non-brokered private placement of secured convertible debentures, raising $545,000 and bringing total proceeds from the offering to $1,385,000. The debentures carry a 15% annual interest rate, mature on December 15, 2026, and are convertible into common shares at $0.05 per share, with accompanying warrants exercisable at $0.08.
Proceeds from the financing are earmarked for lab trials and general working capital, supporting the company’s ongoing development of telomere-based diagnostic and prognostic tests. The transaction, which includes participation by the company’s CFO and a director under related-party rules, remains subject to TSX Venture Exchange approval and imposes a standard hold period on the new securities under Canadian securities regulations.
The most recent analyst rating on (TSE:TELO) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.
Spark’s Take on TSE:TELO Stock
According to Spark, TipRanks’ AI Analyst, TSE:TELO is a Neutral.
The score is primarily weighed down by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity), which elevates financing and dilution risk. Technicals add a secondary headwind with price trading below major moving averages, while valuation is difficult to support given negative earnings and no dividend yield.
To see Spark’s full report on TSE:TELO stock, click here.
More about Telo Genomics Corp
Telo Genomics Corp. is a biotech company specializing in diagnostic and prognostic tests based on chromosomal telomere analysis, with a focus on liquid biopsies and related technologies in oncology and neurological diseases. Leveraging quantitative 3D telomere analysis, molecular biology and artificial intelligence, it aims to deliver accurate tools for pathologists, clinicians, researchers and drug developers, with its lead Telo-MM test targeting treatment decisions in multiple myeloma.
Average Trading Volume: 107,597
Technical Sentiment Signal: Sell
Current Market Cap: C$4.52M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.